China Biopharmaceuticals (01177) independently developed the drug Ruxolitinib tablets "TQ05105 (JAK/ROCK inhibitor)", which has been included in the breakthrough therapy program.

Zh tng cijng APP xn, Zhnggu shngw zhyo (01177) gngb, gi jtun zzh ynf de lu f xn pin "TQ05105 (JAK/ROCK yzh q)" y bi Zhnggu guji yo fi jin d gunl j yo pn shnp zhngxn (CDE) nr tp xng zhlio yow chngx (BTD), yngy mnghu yw zhh bng (cGVHD) de zhlio. Smart Finance and Economics APP News, China Biotech (01177) announced that the group's self-developed Ravascitinib tablets "TQ05105 (JAK/ROCK inhibitor)" have been included in the Breakthrough Therapy Designation program (BTD) by the China National Drug Administration Drug Evaluation Center (CDE) for the treatment of chronic graft-versus-host disease (cGVHD).